| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
COG-1410 targets the receptor-binding domain of apolipoprotein E (apoE), a protein involved in lipid metabolism and neuroprotection. By mimicking the functional properties of apoE, the peptide modulates signaling pathways involved in neuroprotection and inflammation. The compound's mechanism involves binding to apoE receptors and activating downstream survival pathways in neurons and glial cells.
|
|---|---|
| ln Vitro |
Cog1410 (1-25 μm; 48 h) inhibits BV2 astrocytes' synthesis and release of NO and TNFα [1].
In vitro, COG-1410 acts as an apoE peptide mimetic with enhanced stability and bioactivity. It has been shown to exert neuroprotective effects in cell-based models of neuronal injury. The compound enhances retinal ganglion cell survival by attenuating inflammation and apoptosis. Its activity is typically assessed by measuring neuronal survival, inflammatory cytokine levels, and apoptotic markers in treated cells. |
| ln Vivo |
In mice, COG1410 (0.3-0.6 mg/kg; single intravenous injection) dramatically enhanced both long-term tests of spatial learning and memory and short-term tests of vestibular motor function [1]. Improved vestibular motor function, less post-stroke motor discomfort, and a reduction in the amount of the ipsilateral hemisphere infarct are all brought about by COG1410 (0.8 mg/kg; single intravenous injection) [2].
In vivo, COG-1410 exerts neuroprotective and anti-inflammatory effects in a murine model of traumatic brain injury (TBI). It enhances retinal ganglion cell survival by attenuating inflammation and apoptosis following optic nerve injury. The compound's neuroprotective effects make it a valuable tool for studying the therapeutic potential of apoE mimetics in neurological disorders. |
| Enzyme Assay |
As a peptide mimetic, COG-1410 is not typically evaluated in cell-free receptor binding assays in the same manner as small molecules. Its activity is assessed by measuring its binding affinity to apoE receptors using surface plasmon resonance or ELISA-based binding assays. The peptide's ability to compete with native apoE for receptor binding can be evaluated using radiolabeled apoE in competitive binding assays.
|
| Cell Assay |
In vitro cell-based experiments with COG-1410 typically involve primary neuronal cultures or cell lines subjected to injury paradigms such as oxidative stress, excitotoxicity, or serum deprivation. Cells are treated with the peptide, and neuroprotective effects are assessed by measuring cell viability, apoptosis markers (e.g., caspase-3 activation), and inflammatory cytokine production.
|
| Animal Protocol |
Animal/Disease Models: Male C57Bl/6J mice (12-16 weeks) TBI[1]
Doses: 0.3, 0.6 mg/kg Route of Administration: Single intravenous (iv) (iv)injection through tail vein Experimental Results: Motor function improved 1-5 days after injury . Dramatically improve cognitive impairment. Reduce the number of damaged hippocampal neurons. Inhibits microglial activation. In vivo animal experiments with COG-1410 have been conducted in murine models of traumatic brain injury (TBI). In typical protocols, mice undergo controlled cortical impact or fluid percussion injury to induce TBI. COG-1410 is administered via various routes (e.g., intraperitoneal, intravenous) at specific doses and time points post-injury. Neurological outcomes, cognitive function, and histological analysis of brain tissue are assessed. |
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is publicly available for COG-1410. As a peptide, its absorption, distribution, metabolism, and excretion (ADME) properties would be expected to differ from small molecules. The peptide has a molecular weight of 1408.78 and a molecular formula of C64H121N21O14. Its half-life and bioavailability have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is publicly available for COG-1410. In preclinical studies, the peptide has shown neuroprotective effects without reported significant toxicity. The compound is for research use only and is not intended for human therapeutic applications. Further toxicological studies would be needed to fully characterize its safety profile.
|
| References |
[1]. Laskowitz DT, et, al. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurotrauma. 2007 Jul;24(7):1093-107.
[2]. Tukhovskaya EA, et, al. COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia. J Neurosci Res. 2009 Feb 15;87(3):677-82. [3]. Kuai L, et, al. Apolipoprotein E-Mimetic Peptide COG1410 Enhances Retinal Ganglion Cell Survival by Attenuating Inflammation and Apoptosis Following TONI. Front Neurosci. 2019 Sep 13;13:980. |
| Additional Infomation |
COG-1410 has a molecular formula of C64H121N21O14 and a molecular weight of 1408.78. It is an apolipoprotein E (apoE) peptide mimetic containing the amino acid sequence of the receptor-binding domain of apoE. The peptide exerts neuroprotective and anti-inflammatory effects in murine models of TBI. It is available for research purposes only.
|
| Molecular Formula |
C64H121N21O14
|
|---|---|
| Molecular Weight |
1408.8
|
| Exact Mass |
1407.94
|
| CAS # |
878009-24-6
|
| Related CAS # |
Biotin-COG1410 TFA
|
| PubChem CID |
72941932
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.603
|
| LogP |
-1.87
|
| Hydrogen Bond Donor Count |
20
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
49
|
| Heavy Atom Count |
99
|
| Complexity |
2720
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
[C@@H](CCCNC(N)=N)(NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N)CC(C)C
|
| InChi Key |
RPCLHYWMLWFFTE-VKTQGLPSSA-N
|
| InChi Code |
InChI=1S/C64H121N21O14/c1-34(2)29-44(49(67)88)78-55(94)45(30-35(3)4)79-53(92)42(24-20-28-73-62(70)71)76-54(93)43(22-16-18-26-66)82-59(98)63(11,12)84-57(96)47(32-37(7)8)80-52(91)40(21-15-17-25-65)75-51(90)41(23-19-27-72-61(68)69)77-56(95)46(31-36(5)6)83-60(99)64(13,14)85-58(97)48(33-86)81-50(89)38(9)74-39(10)87/h34-38,40-48,86H,15-33,65-66H2,1-14H3,(H2,67,88)(H,74,87)(H,75,90)(H,76,93)(H,77,95)(H,78,94)(H,79,92)(H,80,91)(H,81,89)(H,82,98)(H,83,99)(H,84,96)(H,85,97)(H4,68,69,72)(H4,70,71,73)/t38-,40-,41-,42-,43-,44-,45-,46-,47-,48-/m0/s1
|
| Chemical Name |
(S)-6-amino-N-((S)-1-(((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)-2-((5S,8S,11S,14S,20S,23S)-8-(4-aminobutyl)-11-(3-guanidinopropyl)-20-(hydroxymethyl)-5,14-diisobutyl-2,2,17,17,23-pentamethyl-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazahexacosanamido)hexanamide
|
| Synonyms |
COG-1410 COG 1410 COG1410
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~35.49 mM)
H2O : ~25 mg/mL (~17.75 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (1.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 14.29 mg/mL (10.14 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with heating and sonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7098 mL | 3.5491 mL | 7.0982 mL | |
| 5 mM | 0.1420 mL | 0.7098 mL | 1.4196 mL | |
| 10 mM | 0.0710 mL | 0.3549 mL | 0.7098 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA